{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:52Z","timestamp":1792597672776,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Omalizumab is a recommended second-line therapy for chronic urticaria (CU), yet clinical evidence regarding long-term drug survival and determinants of discontinuation remains limited. Understanding drug survival patterns may inform clinical decision-making and patient stratification.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the long-term drug survival of omalizumab in patients with CU and identify factors associated with discontinuation.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Embase, and Web of Science were systematically searched from database inception to January 20, 2026.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included. Studies lacking survival data or sufficient information for reconstruction of survival curves were excluded.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Time-to-event data were reconstructed from published Kaplan-Meier curves using a validated algorithm implemented in the IPDfromKM framework. Pooled hazard ratios (HRs) were synthesized using a random-effects meta-analysis. Analyses followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes included overall drug survival and reasons for discontinuation. Secondary outcomes included predictors of discontinuation, expressed as HRs with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4). Over a 7-year follow-up period, patients continued to receive treatment for a mean of 3.75 years (95% CI, 3.62-3.87). Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon. Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41), while an atopic background was associated with an increased risk of discontinuation due to well-controlled disease.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events. Autoimmune comorbidities (mainly thyroid-related) were associated with reduced drug survival, primarily due to lack of efficacy, whereas atopic comorbidities were associated with discontinuation after disease control, underscoring the need for improved endotype-driven treatment strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.2043","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:35Z","timestamp":1788966035000},"page":"1046","source":"Crossref","is-referenced-by-count":0,"title":["Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria"],"prefix":"10.1001","volume":"162","author":[{"given":"Alhasan","family":"Altayf","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Azzaytuna University, Tarhuna, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Kolkhir","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukhtar","family":"Alwefati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Tripoli, Tripoli, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[{"name":"Dermatology Center, Hospital CUF Descobertas, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranad","family":"Jirafa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Tripoli, Tripoli, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Zuberbier","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Korea University, Anam-ro, Seongbuk-gu, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"doi260023r1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review.","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"key":"doi260023r2","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","article-title":"The international guideline for the definition, classification, diagnosis and management of urticaria.","author":"Zuberbier","year":"2026","journal-title":"Allergy"},{"issue":"3","key":"doi260023r3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"doi260023r4","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s13555-025-01461-8","article-title":"Urticaria voices: real-world treatment patterns and outcomes in chronic spontaneous urticaria.","volume":"15","author":"Bernstein","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"doi260023r5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00403-025-04461-y","article-title":"Efficacy and safety of remibrutinib in chronic spontaneous urticaria: a systematic review and meta-analysis of data up to 24 weeks.","volume":"318","author":"Altayf","year":"2026","journal-title":"Arch Dermatol Res"},{"key":"doi260023r6","doi-asserted-by":"publisher","DOI":"10.1111\/all.70199","article-title":"Unmet needs in treatment escalation for chronic spontaneous urticaria: findings from the CURE Registry.","author":"Kolkhir","year":"2026","journal-title":"Allergy"},{"issue":"10","key":"doi260023r7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"doi260023r8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence.","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi260023r9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report.","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"issue":"12","key":"doi260023r10","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.jaip.2023.08.033","article-title":"Omalizumab drug survival in chronic urticaria: a retrospective multicentric French study.","volume":"11","author":"Litovsky","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"doi260023r11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamadermatol.2024.2056","article-title":"Multinational drug survival study of omalizumab in patients with chronic urticaria and potential predictors for discontinuation.","volume":"160","author":"Soegiharto","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi260023r12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/all.13714","article-title":"Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.","volume":"74","author":"Spekhorst","year":"2019","journal-title":"Allergy"},{"issue":"71","key":"doi260023r13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"doi260023r14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors.","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi260023r15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"doi260023r16","doi-asserted-by":"publisher","DOI":"10.1177\/23814683221077643","article-title":"A method for reconstructing individual patient data from Kaplan-Meier survival curves that incorporate marked censoring times.","volume":"7","author":"Rogula","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"2","key":"doi260023r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263661","article-title":"Methodology to standardize heterogeneous statistical data presentations for combining time-to-event oncologic outcomes.","volume":"17","author":"Hebert","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"doi260023r18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers.","volume":"23","author":"Han","year":"2022","journal-title":"Korean J Radiol"},{"issue":"6","key":"doi260023r19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/1078-0432.CCR-13-2125","article-title":"Getting more out of survival data by using the hazard function.","volume":"20","author":"Hess","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"doi260023r20","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.20737","article-title":"Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria.","volume":"39","author":"Zhang","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi260023r21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s40629-023-00278-1","article-title":"Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria.","volume":"33","author":"Fabi","year":"2024","journal-title":"Allergo J Int"},{"issue":"18","key":"doi260023r22","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.3390\/jcm13185610","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria in adults and adolescents: an eight-year real-life experience.","volume":"13","author":"Calzari","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"doi260023r23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/pai.13426","article-title":"Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.","volume":"32","author":"Dekkers","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"doi260023r24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.18553\/jmcp.2018.24.7.598","article-title":"Real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the United States.","volume":"24","author":"Ke","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"doi260023r25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","article-title":"Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review.","volume":"12","author":"Balp","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi260023r26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40257-023-00761-z","article-title":"Stepping down treatment in chronic spontaneous urticaria: what we know and what we don\u2019t know.","volume":"24","author":"Terhorst-Molawi","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"doi260023r27","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.5826\/dpc.1503a5196","article-title":"Factors influencing relapse after omalizumab in chronic urticaria: does the method of discontinuation influence relapse?","volume":"15","author":"\u00dcst\u00fcn","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"doi260023r28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1584771","article-title":"Chronic inducible urticaria - having more than one is common and clinically relevant.","volume":"16","author":"Lebedkina","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"doi260023r29","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria.","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"doi260023r30","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa.","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"doi260023r31","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria.","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"issue":"8","key":"doi260023r32","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria.","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"issue":"10","key":"doi260023r33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria.","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"doi260023r34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bjd.16593","article-title":"IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.","volume":"179","author":"Cugno","year":"2018","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi260023r35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1159\/000526205","article-title":"Comparison of the patients with chronic urticaria who responded and did not respond to omalizumab treatment: a single-center retrospective study.","volume":"183","author":"Cakmak","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"doi260023r36","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.jaip.2023.06.026","article-title":"The crucial role of IgE as a predictor of treatment response to omalizumab in chronic spontaneous urticaria.","volume":"11","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"doi260023r37","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1451296","article-title":"IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria.","volume":"5","author":"Ensina","year":"2025","journal-title":"Front Allergy"},{"issue":"10","key":"doi260023r38","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria.","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"doi260023r39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/MS9.0000000000004298","article-title":"A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib.","volume":"88","author":"Jan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"doi260023r40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaip.2025.11.038","article-title":"Systemic treatments for chronic spontaneous urticaria: anti-IgE and beyond.","volume":"14","author":"Hsu","year":"2026","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853489\/jamadermatology_altayf_2026_oi_260023_1792511080.03982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:36Z","timestamp":1792594836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853489"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.2043","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}